Journal of Korean Academy of Nursing (대한간호학회지)

Korean Society of Nursing Science (한국간호과학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Digital Health Interventions on Psychotic Symptoms among Persons with Severe Mental Illness in Community: A Systematic Review and Meta-Analysis

디지털 헬스 중재가 지역사회 중증정신질환자의 정신병적 증상에 미치는 효과: 체계적 문헌고찰 및 메타분석

  • Received : 2022.10.06
  • Accepted : 2023.01.31
  • Published : 2023.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study aimed to evaluate the effects of digital health interventions on the psychotic symptoms among people with severe mental illness in the community. Methods: A systematic review and meta-analysis were conducted in accordance with the Cochrane Intervention Research Systematic Review Manual and PRISMA. A literature search was conducted of published randomized controlled trials (RCTs) for digital health interventions from January 2022 to April 2022. RevMan software 5.3 was used for quality assessment and meta-analysis. Results: A total 14 studies out of 9,864 studies were included in the review, and 13 were included in meta-analysis. The overall effect size of digital health interventions on psychotic symptoms was - 0.21 (95% CI = - 0.32 to - 0.10). Sub-analysis showed that the reduction of the psychotic symptoms was effective in the schizophrenia spectrum group (SMD = - 0.22; 95% CI = - 0.36 to - 0.09), web (SMD = - 0.41; 95% CI = - 0.82 to 0.01), virtual reality (SMD = - 0.33; 95% CI = - 0.56 to - 0.10), mobile (SMD = - 0.15; 95% CI = - 0.28 to - 0.03), intervention period of less than 3 months (SMD = - 0.23; 95% CI = - 0.35 to - 0.11), and non-treatment group (SMD = - 0.23; 95% CI = - 0.36 to - 0.11). Conclusion: These findings suggest that digital health interventions alleviate psychotic symptoms in patients with severe mental illnesses. However, well-designed digital health studies should be conducted in the future.

Keywords

References

  1. Sullivan SA, Kounali D, Cannon M, David AS, Fletcher PC, Holmans P, et al. A population-based cohort study examining the incidence and impact of psychotic experiences from childhood to adulthood, and prediction of psychotic disorder. The American Journal of Psychiatry. 2020;177(4):308-317. https://doi.org/10.1176/appi.ajp.2019.19060654
  2. Yoon SJ, Kim YE, Lee HG, Chung SG, Choi MM, Ha KH, et al. A survey on the medical system for people with severe and mental disorders. Seoul: National Human Rights Commission of Korea; 2019 Dec. Report No.: 11-1620000-000764-01.
  3. Ruggeri M, Leese M, Thornicroft G, Bisoffi G, Tansella M. Definition and prevalence of severe and persistent mental illness. The British Journal of Psychiatry. 2000;177(2):149-155. https://doi.org/10.1192/bjp.177.2.149
  4. Joa I, Gisselgard J, Bronnick K, McGlashan T, Johannessen JO. Primary prevention of psychosis through interventions in the symptomatic prodromal phase, a pragmatic Norwegian Ultra High Risk study. BMC Psychiatry. 2015;15:89. https://doi.org/10.1186/s12888-015-0470-5
  5. Rus-Calafell M, Schneider S. Are we there yet?!-a literature review of recent digital technology advances for the treatment of early psychosis. Mhealth. 2020;6:3. https://doi.org/10.21037/mhealth.2019.09.14
  6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Publishing; 2013. p. 87-122.
  7. Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, et al. Risk factors for relapse following treatment for first episode psychosis: A systematic review and meta-analysis of longitudinal studies. Schizophrenia Research. 2012;139(1-3):116-128. https://doi.org/10.1016/j.schres.2012.05.007
  8. Ben-Zeev D, Chander A, Tauscher J, Buck B, Nepal S, Campbell A, et al. A smartphone intervention for people with serious mental illness: Fully remote randomized controlled trial of CORE. Journal of Medical Internet Research. 2021;23(11):e29201. https://doi.org/10.2196/29201
  9. World Health Organization (WHO). mhGAP training manuals for the mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings, version 2.0 (‎ for field testing). Geneva: World Health Organization; 2017. Report No.: WHO/MSD/MER/17.6.
  10. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet. 2019;394(10202):939-951. https://doi.org/10.1016/S0140-6736(19)31135-3
  11. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. The American Journal of Psychiatry. 2002;159(6):1018-1028. https://doi.org/10.1176/appi.ajp.159.6.1018
  12. Larson MK, Walker EF, Compton MT. Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders. Expert Review of Neurotherapeutics. 2010;10(8):1347-1359. https://doi.org/10.1586/ern.10.93
  13. Guhne U, Weinmann S, Riedel-Heller SG, Becker T. Psychosocial therapies in severe mental illness: Update on evidence and recommendations. Current Opinion in Psychiatry. 2020;33(4):414-421. https://doi.org/10.1097/YCO.0000000000000618
  14. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2009. Schizophrenia Bulletin. 2010;36(1):94-103. https://doi.org/10.1093/schbul/sbp130
  15. Lee SY, Chae SM, Jeon JA, Yoon SM, Cha MR, Jung JW, et al. Strategies for securing the local mental health promotion service supply system - focusing on the management of severe mental illness in the community. Sejong: Korea Institute for Health and Social Affairs; 2018 Dec. Report No.: Research Monographs 2018-26.
  16. Lee YM. National mental health survey. Seoul: National Center for Mental Health (KR); 2021 Dec. Report No.: 11-1352629-000065-01.
  17. Corrigan PW, Druss BG, Perlick DA. The impact of mental illness stigma on seeking and participating in mental health care. Psychological Science in the Public Interest. 2014;15(2):37-70. https://doi.org/10.1177/1529100614531398
  18. Murray E, Hekler EB, Andersson G, Collins LM, Doherty A, Hollis C, et al. Evaluating digital health interventions: Key questions and approaches. American Journal of Preventive Medicine. 2016;51(5):843-851. https://doi.org/10.1016/j.amepre.2016.06.008
  19. Bell I, Pot-Kolder RMCA, Wood SJ, Nelson B, Acevedo N, Stainton A, et al. Digital technology for addressing cognitive impairment in recent-onset psychosis: A perspective. Schizophrenia Research: Cognition. 2022;28:100247. https://doi.org/10.1016/j.scog.2022.100247
  20. Moulin T, Dobson J, Hixson JD, Arvanitis TN. Digital Health: The journal's pioneering journey 6 years on. Digital Health. 2021;7:20552076211034034. https://doi.org/10.1177/20552076211034034
  21. Krzystanek M, Borkowski M, Skalacka K, Krysta K. A telemedicine platform to improve clinical parameters in paranoid schizophrenia patients: Results of a one-year randomized study. Schizophrenia Research. 2019;204:389-396. https://doi.org/10.1016/j.schres.2018.08.016
  22. Garety P, Ward T, Emsley R, Greenwood K, Freeman D, Fowler D, et al. Effects of SlowMo, a blended digital therapy targeting reasoning, on paranoia among people with psychosis: A randomized clinical trial. JAMA Psychiatry. 2021;78(7):714-725. https://doi.org/10.1001/jamapsychiatry.2021.0326
  23. Dellazizzo L, Potvin S, Phraxayavong K, Dumais A. Oneyear randomized trial comparing virtual reality-assisted therapy to cognitive-behavioral therapy for patients with treatment-resistant schizophrenia. NPJ Schizophrenia. 2021;7(1):9. https://doi.org/10.1038/s41537-021-00139-2
  24. Gottlieb JD, Gidugu V, Maru M, Tepper MC, Davis MJ, Greenwold J, et al. Randomized controlled trial of an internet cognitive behavioral skills-based program for auditory hallucinations in persons with psychosis. Psychiatric Rehabilitation Journal. 2017;40(3):283-292. https://doi.org/10.1037/prj0000258
  25. Depp CA, Perivoliotis D, Holden J, Dorr J, Granholm EL. Single-session mobile-augmented intervention in serious mental illness: A three-arm randomized controlled trial. Schizophrenia Bulletin. 2019;45(4):752-762. https://doi.org/10.1093/schbul/sby135
  26. Marono Souto Y, Vazquez Campo M, Diaz Llenderrozas F, Rodriguez lvarez M, Mateos R, Garcia Caballero A. Randomized clinical trial with e-MotionalTraining® 1.0 for social cognition rehabilitation in schizophrenia. Frontiers in Psychiatry. 2018;9:40. https://doi.org/10.3389/fpsyt.2018.00040
  27. Cullen BA, Rodriguez K, Eaton WW, Mojtabai R, Von Mach T, Ybarra ML. Clinical outcomes from the texting for relapse prevention (T4RP) in schizophrenia and schizoaffective disorder study. Psychiatry Research. 2020;292:113346. https://doi.org/10.1016/j.psychres.2020.113346
  28. Naslund JA, Aschbrenner KA. Digital technology for health promotion: Opportunities to address excess mortality in persons living with severe mental disorders. Evidence Based Mental Health. 2019;22(1):17-22. https://doi.org/10.1136/ebmental-2018-300034
  29. Chivilgina O, Elger BS, Jotterand F. Digital technologies for schizophrenia management: A descriptive review. Science and Engineering Ethics. 2021;27(2):25. https://doi.org/10.1007/s11948-021-00302-z
  30. Kim SK, Lee M, Jeong H, Jang YM. Effectiveness of mobile applications for patients with severe mental illness: A meta-analysis of randomized controlled trials. Japan Journal of Nursing Science. 2022;19(3):e12476. https://doi.org/10.1111/jjns.12476
  31. Mohr DC, Azocar F, Bertagnolli A, Choudhury T, Chrisp P, Frank R, et al.; Banbury Forum on Digital Mental Health. Banbury forum consensus statement on the path forward for digital mental health treatment. Psychiatric Services. 2021;72(6):677-683. https://doi.org/10.1176/appi.ps.202000561
  32. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. 2nd ed. Chichester (WS): John Wiley & Sons; 2019. p. 321-374.
  33. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71
  34. Bidwell S, Jensen MF. Etext on health technology assessment (HTA) information resources. Chapter 3: Using a search protocol to identify sources of information: The COSI model [Internet]. Bethesda: National Library of Medicine (US); c2003 [cited 2022 May 20]. Available from: https://www.nlm.nih. gov/archive/20060905/nichsr/ehta/chapter3.html#COSI
  35. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928
  36. Kim SY, Park DA, Seo HJ, Shin SS, Lee SJ, Lee M, et al. Health technology assessment methodology: Systematic review. Seoul: National Evidence-based Healthcare Collaborating Agency (KR); 2020. p. 131-132.
  37. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Eribaum Associates; 1988. p. 22.
  38. Bell IH, Rossell SL, Farhall J, Hayward M, Lim MH, Fielding-Smith SF, et al. Pilot randomised controlled trial of a brief coping-focused intervention for hearing voices blended with smartphone-based ecological momentary assessment and intervention (SAVVy): Feasibility, acceptability and preliminary clinical outcomes. Schizophrenia Research. 2020;216:479-487. https://doi.org/10.1016/j.schres.2019.10.026
  39. Ben-Zeev D, Brian RM, Jonathan G, Razzano L, Pashka N, Carpenter-Song E, et al. Mobile health (mHealth) versus clinic-based group intervention for people with serious mental illness: A randomized controlled trial. Psychiatric Services. 2018;69(9):978-985. https://doi.org/10.1176/appi.ps.201800063
  40. Pot-Kolder RMCA, Geraets CNW, Veling W, van Beilen M, Staring ABP, Gijsman HJ, et al. Virtual-reality-based cognitive behavioural therapy versus waiting list control for paranoid ideation and social avoidance in patients with psychotic disorders: A single-blind randomised controlled trial. Lancet Psychiatry. 2018;5(3):217-226. https://doi.org/10.1016/S2215-0366(18)30053-1
  41. Lewis S, Ainsworth J, Sanders C, Stockton-Powdrell C, Machin M, Whelan P, et al. Smartphone-enhanced symptom management in psychosis: Open, randomized controlled trial. Journal of Medical Internet Research. 2020;22(8):e17019. https://doi.org/10.2196/17019
  42. Craig TK, Rus-Calafell M, Ward T, Leff JP, Huckvale M, Howarth E, et al. AVATAR therapy for auditory verbal hallucinations in people with psychosis: A single-blind, randomised controlled trial. Lancet Psychiatry. 2018;5(1):31-40. https://doi.org/10.1016/S2215-0366(17)30427-3 Erratum in: Lancet Psychiatry. 2018;5(1):e1.
  43. Ghaemi SN, Sverdlov O, van Dam J, Campellone T, Gerwien R. A smartphone-based intervention as an adjunct to standard-of-care treatment for schizophrenia: Randomized controlled trial. JMIR Formative Research. 2022;6(3):e29154. https://doi.org/10.2196/29154
  44. Mojtabai R, Fochtmann L, Chang SW, Kotov R, Craig TJ, Bromet E. Unmet need for mental health care in schizophrenia: An overview of literature and new data from a first-admission study. Schizophrenia Bulletin. 2009;35(4):679-695. https://doi.org/10.1093/schbul/sbp045
  45. Cugelman B. Gamification: What it is and why it matters to digital health behavior change developers. JMIR Serious Games. 2013;1(1):e3. https://doi.org/10.2196/games.3139
  46. National Collaborating Centre for Mental Health (GB). Psychosis and schizophrenia in adults: Treatment and management. Updated ed. London: National Collaborating Centre for Mental Health (GB); 2014. p. 221-222.
  47. Jauhar S, Laws KR, McKenna PJ. CBT for schizophrenia: A critical viewpoint. Psychological Medicine. 2019;49(8):1233- 1236. https://doi.org/10.1017/S0033291718004166
  48. Bighelli I, Salanti G, Huhn M, Schneider-Thoma J, Krause M, Reitmeir C, et al. Psychological interventions to reduce positive symptoms in schizophrenia: Systematic review and network meta-analysis. World Psychiatry. 2018;17(3):316-329. https://doi.org/10.1002/wps.20577
  49. Killaspy H, Harvey C, Brasier C, Brophy L, Ennals P, Fletcher J, et al. Community-based social interventions for people with severe mental illness: A systematic review and narrative synthesis of recent evidence. World Psychiatry. 2022;21(1):96-123. https://doi.org/10.1002/wps.20940
  50. Alvarez-Jimenez M, Alcazar-Corcoles MA, Gonzalez-Blanch C, Bendall S, McGorry PD, Gleeson JF. Online, social media and mobile technologies for psychosis treatment: A systematic review on novel user-led interventions. Schizophrenia Research. 2014;156(1):96-106. https://doi.org/10.1016/j.schres.2014.03.021
  51. Torous J, Bucci S, Bell IH, Kessing LV, Faurholt-Jepsen M, Whelan P, et al. The growing field of digital psychiatry: Current evidence and the future of apps, social media, chatbots, and virtual reality. World Psychiatry. 2021;20(3):318-335. https://doi.org/10.1002/wps.20883
  52. Ben-Zeev D, Brenner CJ, Begale M, Duffecy J, Mohr DC, Mueser KT. Feasibility, acceptability, and preliminary efficacy of a smartphone intervention for schizophrenia. Schizophrenia Bulletin. 2014;40(6):1244-1253. https://doi.org/10.1093/schbul/sbu033
  53. Torous J, Nicholas J, Larsen ME, Firth J, Christensen H. Clinical review of user engagement with mental health smartphone apps: Evidence, theory and improvements. Evidence Based Mental Health. 2018;21(3):116-119. https://doi.org/10.1136/eb-2018-102891
  54. Steare T, O'Hanlon P, Eskinazi M, Osborn D, Lloyd-Evans B, Jones R, et al. Smartphone-delivered self-management for first-episode psychosis: The ARIES feasibility randomised controlled trial. BMJ Open. 2020;10(8):e034927. https://doi.org/10.1136/bmjopen-2019-034927
  55. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Pressure. 1992;1(2):113-119. https://doi.org/10.3109/08037059209077502
  56. Sverdlov O, van Dam J, Hannesdottir K, Thornton-Wells T. Digital therapeutics: An integral component of digital innovation in drug development. Clinical Pharmacology and Therapeutics. 2018;104(1):72-80. https://doi.org/10.1002/cpt.1036
  57. Kim SY, Park DA, Seo HJ, Shin SS, Lee SJ, Lee M, et al. Health technology assessment methodology: Systematic review. Seoul: National Evidence-based Healthcare Collaborating Agency (KR); 2020. p. 140.